Perrigo finally has a deal to divest its prescription business. The company has announced an agreement worth just over $1.5bn for private equity firm Altaris Capital Partners to acquire the “Rx” generics business, with the transaction expected to close by the end of the third quarter of 2021.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?